We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Newborn Screening Test Developed For Deadly Neurological Disorder

By LabMedica International staff writers
Posted on 18 May 2016
A newborn screening test has been introduced that identifies infants with Niemann-Pick disease type C, an often fatal condition in which cholesterol builds up and eventually destroys brain cells.

Although this disease was untreatable in the past, new therapeutics are now in clinical trials, but they are most likely to be effective if treatment is started as early as possible, before neurodegeneration has occurred. More...
Niemann-Pick type C disease (NPC) typically is not diagnosed until at least age two, after neurological symptoms have begun to develop.

A team of collaborating scientists led by those at Washington University School of Medicine (St. Louis, MO, USA) screened more than 5,000 dried blood spot specimens. Of these, 44 were known to be samples from NPC patients; 134 were samples from people who were known carriers; and the remaining 4,992 were control samples from people without the condition. A high-throughput mass spectrometry–based method was developed and validated to measure the glycine-conjugated bile acid in dried blood spots.

The teams used metabolomic profiling to identify potential markers and discovered three unknown bile acids that were increased in plasma from NPC, but not control subjects. The bile acids most elevated in the NPC subjects were identified as 3β,5α,6β-trihydroxycholanic acid and its glycine conjugate, which were shown to be metabolites of cholestane-3β,5α,6β-triol, an oxysterol elevated in NPCs. The NPC patients have about thirty fold higher amounts of this bile acid in the blood than healthy individuals. Importantly, levels of this bile acid also could distinguish between patients with NPC and carriers of the disease who show no symptoms. Analysis of dried blood spots from the controls, the NPC carriers, and the NPC subjects provided 100% sensitivity and specificity in the study samples.

Daniel S. Ory, MD, a Professor of Medicine and the senior author of the study said, “These types of tests can be quite automated. If you’re running 500 samples per day, you can test many specimens at once at robotic handling stations that many state laboratory facilities already have. The cost of materials and labor would be on par with current accepted newborn screening tests. Once established, a reasonable estimate of the cost of running these tests would be less than USD 1 per sample.” The study was published on May 4, 2016, in the journal Science Translational Medicine.

Related Links:
Washington University School of Medicine


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: Schematic diagram of multimodal single-cell MSI using tapping-mode scanning probe electrospray ionization (Photo courtesy of Yoichi Otsuka)

New Technology Improves Understanding of Complex Biological Samples

Tissues are composed of a complex mixture of various cell types, which complicates our understanding of their biological roles and the study of diseases. Now, a multi-institutional team of researchers... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.